(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback